ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by functional connectivity alterations in both motor and extra-motor brain regions. In network analysis, fingerprint represent a valid approach able to assess the subject-specific connectivity features of a given population. Here, we applied the Clinical Connectome Fingerprint (CCF) analysis to source-reconstructed magnetoencephalography (MEG) signals in a cohort of seventy-eight subjects: thirty-nine ALS patients and thirty-nine healthy controls. We set out to develop an identifiability matrix to assess the extent to which each subject was recognisable based on his/her connectome. The analysis was performed in all five canonical frequency bands. Then we built a multilinear regression model to test the ability of “clinical fingerprint” to predict the clinical evolution of disease assessed by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-r), the King’s disease staging system and the Milano-Torino Staging (MiToS) disease staging system. We found a drop in patients’ identifiability in the alpha band compared to the healthy controls. Furthermore, the “clinical fingerprint” was predictive of ALSFRS-r (p=0.0397; β=32.8), King’s (p=0.0001; β= -7.40) and MiToS (p=0.0025; β= -4.9) scores and negatively correlated with King’s and MiToS scales according to Spearman’s correlation. Our results demonstrated the ability of the CCF approach in assessing the individual motor condition and its relationship with ALS disease. Thanks to the subject-specific characteristic of this approach, we hope that further exploration related to its clinical application may help improve the management of disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
this study was funded by University of Naples Parthenope within the project Bando Ricerca Competitiva 2017 (D.R 289/2017)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of University of Campania Luigi Vanvitelli gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all the data produced in the present study are available upon reasonable request to the authors
Abbreviations
- (ALS)
- Amyotrophic Lateral Sclerosis
- (MEG)
- Magnetoencephalography
- (FC)
- Functional Connectome
- (CCF)
- Clinical Connectome Fingerprint
- (PLM)
- Phase linearity measurement
- (ALSFRS-r)
- Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
- (MiToS)
- Milano-Torino Staging disease staging system
- (ROIs)
- Region of interest
- (IM)
- Identifiability matrix
- (ICC)
- Intra-class correlation coefficient
- (SR)
- Success rate
- (LOOCV)
- Leave-one-out-cross validation
